The University of Southampton
University of Southampton Institutional Repository

The role of nitric oxide as a novel therapy to disrupt bacterial biofilms in patients with cystic fibrosis

The role of nitric oxide as a novel therapy to disrupt bacterial biofilms in patients with cystic fibrosis
The role of nitric oxide as a novel therapy to disrupt bacterial biofilms in patients with cystic fibrosis
The lungs of most patients with cystic fibrosis (CF) eventually become chronically infected with the opportunistic pathogen Pseudomonas aeruginosa (PA). This infection is recognised as consisting of free-living bacteria (known as “planktonic bacteria”) and bacteria within aggregates known as “biofilms”. Bacteria within biofilms are more tolerant to antibiotics than their planktonic counterparts. Current CF treatment of infective exacerbations aims to eradicate or control PA infection using aggressive antibiotic regimes. Despite repeated courses of antibiotics used early after initial positive cultures, many patients become permanently infected. This chronic infection/colonisation results in progressive airways obstruction and worsening bronchiectasis. Patients colonised with PA are more unwell and die at a younger age. Work conducted by colleagues had established that low dose nitric oxide (NO) can disrupt pseudomonal biofilms in the laboratory and established a novel combination of assays to study biofilm obtained directly from CF sputa. This proof of concept study aimed to discover whether non-toxic levels of NO, administered to participants during an episode of acute infective exacerbation, could disrupt bacteria from biofilms and increase the effectiveness of antibiotic therapy. A randomised, participant and outcome-assessor blind, proof of concept study was carried out to compare treatment with nitric oxide gas during acute infection with placebo. Twelve participants with CF (aged 12 or above) were randomised to receive 5-7 days of either inhaled nitric oxide gas (10ppm) or placebo (air) in addition to standard intravenous (IV) antibiotics for a pulmonary exacerbation. The primary endpoint was the microbiological effect on proportion of bacteria in biofilms in sputum between baseline and follow-up. Secondary endpoints included laboratory and clinical parameters measured at all time-points including a number of safety measures. There was no difference between the groups in the primary outcome measure of proportion of bacteria in biofilm between baseline and follow-up. In the secondary outcomes, generalised estimating equation analysis showed a significant reduction in bacteria in biofilms in the NO group at the end of 7 days NO therapy (mean log difference between groups for measured number of >20 cell aggregates 3.49 (95%CI 0.32, 6.67; p=0.031) and for biofilm volume 4.47 (95%CI -.04, 8.98; p=0.052)). Safety measures were reassuring and other parameters (including lung function) demonstrated trends in the direction of treatment, but no other results reached significance. All results are impacted by the small number of participants and the wide variability between and within participants. There was no effect seen on bacterial biofilms at follow-up, however, the secondary microbiological outcome data shows preliminary evidence of benefit using low dose NO as adjunctive therapy during the period of treatment. Results show inhaled NO therapy is safe when administered to CF patients during a pulmonary exacerbation alongside IV antibiotic therapy. Further studies are needed to investigate whether inhaled NO, or new drugs in development (e.g. novel targeted NO donor therapies) may have any impact on PA related morbidity and mortality in CF.
University of Southampton
Cathie, Katrina
4b772af2-4b34-45d4-866a-fb934376e1cd
Cathie, Katrina
4b772af2-4b34-45d4-866a-fb934376e1cd
Faust, Saul
f97df780-9f9b-418e-b349-7adf63e150c1
Webb, Jeremy
7d2a2c36-ebb8-477e-b08e-e81c49d21532
Connett, Gary
55d5676c-90d8-46bf-a508-62eded276516

Cathie, Katrina (2016) The role of nitric oxide as a novel therapy to disrupt bacterial biofilms in patients with cystic fibrosis. University of Southampton, Doctoral Thesis, 465pp.

Record type: Thesis (Doctoral)

Abstract

The lungs of most patients with cystic fibrosis (CF) eventually become chronically infected with the opportunistic pathogen Pseudomonas aeruginosa (PA). This infection is recognised as consisting of free-living bacteria (known as “planktonic bacteria”) and bacteria within aggregates known as “biofilms”. Bacteria within biofilms are more tolerant to antibiotics than their planktonic counterparts. Current CF treatment of infective exacerbations aims to eradicate or control PA infection using aggressive antibiotic regimes. Despite repeated courses of antibiotics used early after initial positive cultures, many patients become permanently infected. This chronic infection/colonisation results in progressive airways obstruction and worsening bronchiectasis. Patients colonised with PA are more unwell and die at a younger age. Work conducted by colleagues had established that low dose nitric oxide (NO) can disrupt pseudomonal biofilms in the laboratory and established a novel combination of assays to study biofilm obtained directly from CF sputa. This proof of concept study aimed to discover whether non-toxic levels of NO, administered to participants during an episode of acute infective exacerbation, could disrupt bacteria from biofilms and increase the effectiveness of antibiotic therapy. A randomised, participant and outcome-assessor blind, proof of concept study was carried out to compare treatment with nitric oxide gas during acute infection with placebo. Twelve participants with CF (aged 12 or above) were randomised to receive 5-7 days of either inhaled nitric oxide gas (10ppm) or placebo (air) in addition to standard intravenous (IV) antibiotics for a pulmonary exacerbation. The primary endpoint was the microbiological effect on proportion of bacteria in biofilms in sputum between baseline and follow-up. Secondary endpoints included laboratory and clinical parameters measured at all time-points including a number of safety measures. There was no difference between the groups in the primary outcome measure of proportion of bacteria in biofilm between baseline and follow-up. In the secondary outcomes, generalised estimating equation analysis showed a significant reduction in bacteria in biofilms in the NO group at the end of 7 days NO therapy (mean log difference between groups for measured number of >20 cell aggregates 3.49 (95%CI 0.32, 6.67; p=0.031) and for biofilm volume 4.47 (95%CI -.04, 8.98; p=0.052)). Safety measures were reassuring and other parameters (including lung function) demonstrated trends in the direction of treatment, but no other results reached significance. All results are impacted by the small number of participants and the wide variability between and within participants. There was no effect seen on bacterial biofilms at follow-up, however, the secondary microbiological outcome data shows preliminary evidence of benefit using low dose NO as adjunctive therapy during the period of treatment. Results show inhaled NO therapy is safe when administered to CF patients during a pulmonary exacerbation alongside IV antibiotic therapy. Further studies are needed to investigate whether inhaled NO, or new drugs in development (e.g. novel targeted NO donor therapies) may have any impact on PA related morbidity and mortality in CF.

Text
Katrina Cathie final MD e thesis - Version of Record
Available under License University of Southampton Thesis Licence.
Download (9MB)

More information

Published date: December 2016

Identifiers

Local EPrints ID: 435864
URI: http://eprints.soton.ac.uk/id/eprint/435864
PURE UUID: 82e90f7d-8659-4714-ac82-44df308c9558
ORCID for Saul Faust: ORCID iD orcid.org/0000-0003-3410-7642
ORCID for Gary Connett: ORCID iD orcid.org/0000-0003-1310-3239

Catalogue record

Date deposited: 22 Nov 2019 17:30
Last modified: 17 Mar 2024 03:51

Export record

Contributors

Author: Katrina Cathie
Thesis advisor: Saul Faust ORCID iD
Thesis advisor: Jeremy Webb
Thesis advisor: Gary Connett ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×